Skip to main content

Table 2 In vitro inhibitory effect (expressed as IC50) of the antibiotics tested against PAF-induced aggregation of rPRP

From: In vitro anti-inflammatory and anti-coagulant effects of antibiotics towards Platelet Activating Factor and thrombin

 

IC501towards PAF in rPRP (μg/mL)

Bioactive

Compound

Median

Min

Max

Geometric Mean

95% Confidence Interval

Clarithromycin

49.6

33.2

78.4

50.5

17.4 thru 147.1

Azithromycin

23.3

11.9

29.6

20.2

6.2 thru 65.2

Linezolid

ND

-

-

-

-

Amikacin

9.6

5.4

11.2

8.3

3.2 thru 21.7

Netilmicin

384.6

365.9

430.4

392.7

319.4 thru 482.9

Daptomycin

384.5

375.8

465.8

406.8

303.5 thru 545.2

Piperacillin/Tazobactam

837.1/86.4

765.0/76.9

889.6/102.3

829.0/87.9

686.5 thru 1001.0/61.6 thru 125.6

Ceftazidime

385.5

345.6

412.9

380.3

304.3 thru 475.3

Tigecycline

26.0

20.8

27.3

24.6

17.1 thru 35.2

Vancomycin

70.9

62.1

73.7

68.7

55.0 thru 86.0

Meropenem

ND

-

-

-

-

  1. Experiments were conducted three times using different platelets preparations. 1IC50 values are expressed as μg/mL of bioactive compound in the aggregometer cuvette. Final concentration of PAF in the aggregometer cuvette when tested when tested in rPRP was 2.24 × 10-7M. rPRP: rabbit Platelet Reach Plasma; ND: Not detected inhibition against PAF-induced platelet aggregation.
Back to article page

Journal of Inflammation

ISSN: 1476-9255

Contact us